Niclosamide methanol solvate and niclosamide hydrate: Structure, solvent inclusion mode and implications for properties

Acta Crystallographica Section C: Structural Chemistry

Volumn 70, Issue 8, 2014, Pages 758-763

  Harriss, Bethany I ^a   Wilson, Claire ^b   Radosavljevic Evans, Ivana ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

^b DIAMOND LIGHT SOURCE LTD   (United Kingdom)

Author keywords

crystal structure; desolvation; hydrogen bonding; niclosamide hydrate; niclosamide methanol solvate; pharmaceutical compounds; PXRD measurements; solvent inclusion mode

Indexed keywords

CRYSTAL STRUCTURE; HYDRATES; HYDRATION; HYDROGEN BONDS; METHANOL; X RAY DIFFRACTION;

AMBIENT CONDITIONS; DESOLVATION; NICLOSAMIDE METHANOL SOLVATE; PHARMACEUTICAL COMPOUNDS; POWDER X-RAY DIFFRACTION (PXRD); SINGLE CRYSTAL X-RAY DIFFRACTION; SOLVENT INCLUSIONS; STRUCTURAL STUDIES;

ORGANIC SOLVENTS;

2 HYDROXYBENZAMIDE; 2-HYDROXYBENZAMIDE; BENZAMIDE DERIVATIVE; DRUG DERIVATIVE; METHANOL; NICLOSAMIDE; NICLOSAMIDE(5 CHLORO N (2 CHLORO 4 NITROPHENYL) 2 HYDROXYBENZAMIDE; NICLOSAMIDE(5-CHLORO-N-(2-CHLORO-4-NITROPHENYL)-2-HYDROXYBENZAMIDE; SOLVENT;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTAL STRUCTURE; DESOLVATION; HYDROGEN BOND; NICLOSAMIDE METHANOL SOLVATE; PHARMACEUTICAL COMPOUNDS; PXRD MEASUREMENTS; SOLVENT INCLUSION MODE; X RAY DIFFRACTION;

CRYSTAL STRUCTURE; DESOLVATION; HYDROGEN BONDING; NICLOSAMIDE HYDRATE; NICLOSAMIDE METHANOL SOLVATE; PHARMACEUTICAL COMPOUNDS; PXRD MEASUREMENTS; SOLVENT INCLUSION MODE;

BENZAMIDES; METHANOL; MOLECULAR STRUCTURE; NICLOSAMIDE; SOLVENTS; X-RAY DIFFRACTION;

EID: 84905495570     PISSN: None     EISSN: 20532296     Source Type: Journal    
DOI: 10.1107/S2053229614015496     Document Type: Article

References (21)

1. Altomare, A., Cascarano, G., Giacovazzo, C., Guagliardi, A., Burla, M. C., Polidori, G. & Camalli, M. (1994). J. Appl. Cryst. 27, 435.
2. Betteridge, P. W., Carruthers, J. R., Cooper, R. I., Prout, K. & Watkin, D. J. (2003). J. Appl. Cryst. 36, 1487.
3. Caira, M. R., van Tonder, E. C., De Villiers, M. M. & Lotter, A. P. (1998). J. Inclusion Phenom. Mol. Recognit. Chem. 31, 1-16.
4. Clarke, H. D., Hickey, M. B., Moulton, B., Perman, J. A., Peterson, M. L., Wojtas, L., Almarsson, O. & Zaworotko,M. J. (2012). Cryst. Growth Des. 12, 4194-4201.
5. Coelho, A. A. (2003). J. Appl. Cryst. 36, 86-95.
6. Coelho, A. A., Evans, J. S. O., Evans, I. R., Kern, A. & Parsons, S. (2011). Powder Diffr. 26, S22-S25.
7. Flack, H. D. (1983). Acta Cryst. A39, 876-881.
8. Helfman, D. M. (2011). J. Natl Cancer Inst. 103, 991-992.
9. Imperi, F.,Massai, F., Pillai, C. R., Longo, F., Zennaro, E., Rampioni, G., Visca, P. & Leoni, L. (2013). Antimicrob. Agents Chemother. 57, 996-1005.
10. Koshelev, L. & Bekhli, A. F. (1974). Khim. Farm. Zh. 8, 57-60.
11. Macrae, C. F., Bruno, I. J., Chisholm, J. A., Edgington, P. R., McCabe, P., Pidcock, E., Rodriguez-Monge, L., Taylor, R., van de Streek, J. & Wood, P. A. (2008). J. Appl. Cryst. 41, 466-470.
12. Manek, R. V. & Kolling, W. M. (2004). AAPS PharmSciTech, 5(1), 101-108.
13. Pawley, G. S. (1981). J. Appl. Cryst. 14, 357-361.
14. Rigaku (2010). CrystalClear-SM Expert. Rigaku Corporation, Tokyo, Japan.
15. Sanphui, P., Kumar, S. S. & Nangia, A. (2012). Cryst. Growth Des. 12, 4588- 4599.
16. Steiner, T. (2002). Angew. Chem. Int. Ed. 41, 48-76.
17. Tian, F., Qu, H., Louhi-Kultanen, M. & Rantanen, J. (2010). Chem. Eng. Technol. 33, 833-838.
18. Tonder, E. C. van, Mahlatji, M. D., Malan, S. F., Liebenberg, W., Caira, M. R., Song, M. N. & de Villiers, M. M. (2004). AAPS PharmSciTech, 5(1), 86-95.
19. Tonder, E. C. van, Maleka, T. S. P., Liebenberg,W., Song, M. N.,Wurster, D. E. & de Villiers, M. M. (2004). Int. J. Pharm. 269, 417-432.
20. Weinbach, E. C. & Garbus, J. (1969). Nature, 221, 1016-1018.
21. Yo, Y.-T., Lin, Y.-W., Wang, Y.-C., Balch, C., Huang, R.-L., Chan, M. W. Y., Sytwu, H. K., Chen, C.-K., Chang, C.-C., Nephew, K. P., Huang, T., Yu, M.-H. & Lai, H.-C. (2012). Mol. Cancer Ther. 11, 1703-1712.